Accessibility Menu
Medicenna Therapeutics logo

Medicenna Therapeutics(OTC) MDNA

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-77%
5 Year-86%
1 Year-57%
1 Month+37%
N/A
Medicenna Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.342026-09-01
Medicenna Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.01%USD 0.342026-08-25
1 month+37.2%USD 0.252026-07-31
3 month+3.94%USD 0.332026-06-03
Year to date-49.28%USD 0.682025-12-31
1 year-57.13%USD 0.802025-08-29
3 year-7.27%USD 0.372023-09-01
5 year-85.88%USD 2.432021-09-02
Since inception-77.04%USD 1.502017-09-20

Medicenna Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$14.07M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Jun 25, 2024

MDNA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medicenna Therapeutics

Medicenna Therapeutics Corp. is an innovative immunotherapy company focused on developing Superkines and "empowered Superkines" for cancer treatment and other diseases. The company is advancing its lead candidate, MDNA55, which has shown promise in clinical trials for recurrent glioblastoma.

Products and Services
  • MDNA55: Targeted therapy for recurrent glioblastoma
  • MDNA11: Enhanced IL-2 for immune cell activation
  • MDNA209: IL-2 antagonist for autoimmune conditions
Growth Outlook
  • MDNA55 has completed a Phase IIb trial, indicating strong clinical progress
  • Pipeline includes multiple candidates targeting various cancers and autoimmune diseases
  • Proprietary BiSKITs platform enhances development of custom Superkines
Financial Highlights
  • Recent quarterly net income of -$3.72 million, reflecting ongoing R&D investments
  • Cash and cash equivalents of $25.69 million as of September 30, 2023
  • Trailing twelve months (TTM) cash flow metrics indicate a focus on growth despite losses
Medicenna Therapeutics Corp. is positioned in the biotechnology sector, leveraging its proprietary technologies to develop advanced therapies. The company’s focus on immunotherapy aligns with growing trends in cancer treatment, making it a noteworthy player in the healthcare landscape. The recent clinical advancements and a robust pipeline suggest potential for future growth, despite current financial challenges. The company maintains a solid cash position, which supports ongoing research and development efforts.
AI Generated • Aug 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

20

CEO

Fahar Merchant, PhD

Website

www.medicenna.com

Headquarters

Toronto, ON M4W 3E2, CA

MDNA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-360.29%

Return on Capital

-55.29%

Return on Assets

-225.03%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$22.58M

EBITDA

-CA$19.14M

Operating Cash Flow

-CA$13.34M

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$13.34M

Cash & ST Invst.

CA$25.69M

Total Debt

CA$0.00

Medicenna Therapeutics Performance Analysis

Medicenna Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31CAD 0N/A
20242024-03-31CAD 0N/A
20252025-03-31CAD 0N/A
20262026-03-31CAD 0N/A
Medicenna Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-12-31N/A
Q42023-03-31N/A
Q12023-06-30N/A
Q22023-09-30N/A
Medicenna Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31CAD -0.12-64.6%
20242024-03-31CAD -0.27131.1%
20252025-03-31CAD -0.11-59.2%
20262026-03-31CAD -0.1644.6%
Medicenna Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-12-31-28.3%
Q42023-03-31-305.6%
Q12023-06-3052.4%
Q22023-09-30-30.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

16

N/A

Net Income

-CA$3.72M

-251.9%

EBITDA

-CA$6.81M

-43.9%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

CA$25.69M

-35.8%

Total Debt

CA$0.00

N/A

Accounts Receivable

CA$306.00K

+105.4%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$0.00

N/A

Return on Assets

-2.25%

N/A

Return on Invested Capital

-13.45%

N/A

Free Cash Flow

-CA$3.92M

+10.9%

Operating Cash Flow

-CA$3.92M

+10.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CYCCCyclacel Pharmaceuticals, Inc.
$6.37-5.98%
AMTIApplied Molecular Transport Inc.
$0.26-3.13%
KRROKorro Bio, Inc.
$12.24-2.00%
HURATuHURA Biosciences, Inc.
$2.03-4.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$14.06+0.06%
NVDANvidia
$217.44-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.33-0.06%
INTCIntel
$88.97-0.01%

Questions About MDNA

What is the current price of Medicenna Therapeutics?

Medicenna Therapeutics is trading at N/A per share.

What is the 52-week range for Medicenna Therapeutics?

Over the past 52 weeks, Medicenna Therapeutics has traded between N/A and N/A.

How much debt does Medicenna Therapeutics have?

As of the most recent reporting period, Medicenna Therapeutics reported total debt of CA$73.30K.

How much cash does Medicenna Therapeutics have on hand?

Medicenna Therapeutics reported CA$4.01M in cash and cash equivalents in its most recent financial results.

What is Medicenna Therapeutics’s dividend yield?

Medicenna Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services